Assoc. Prof. Dr. Qi Feng | Internal Medicine | Best Researcher Award

Qi Feng is an Associate Professor at the Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou University. He received his PhD in Chemical Biology from Osaka University, and holds master’s and bachelor’s degrees from Jilin University and Henan University of Science and Technology, respectively. His research focuses on diabetic nephropathy, renal pharmacology, immunology, ferroptosis, and metabolism. With postdoctoral experience in Japan and an H-index of 19, he is an active contributor to nephrology and biomedical research.

Assoc. Prof. Dr. Qi Feng | The First Affiliated Hospital of Zhengzhou University | China

ORCID ID

Education

Qi Feng earned his Doctor of Science degree in Chemical Biology from Osaka University in Japan, where he conducted research under the guidance of Professor Koichi Fukase from 2014 to 2017. Prior to that, he completed his Master of Science in Bioengineering at Jilin University, China, from 2011 to 2014 under the supervision of Professor Yuxin Chen. He began his academic journey with a Bachelor of Science in Biotechnology at Henan University of Science and Technology, China, graduating in 2011.

Experience

Qi Feng is currently serving as an Associate Professor at the Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou University, China, a position he has held since January 2025. Before this role, he worked as an Assistant Professor at the same institute from August 2018 to December 2024. His international experience includes a postdoctoral fellowship at Osaka University in Japan from September 2017 to March 2018.

Awards and Recognitions

With an H-index of 19 and an active academic profile on ResearchGate, Qi Feng has established himself as a respected researcher in nephrology and biomedical sciences. He has made significant contributions to the understanding of diabetic nephropathy and continues to publish high-impact studies in this field.

Skills and Certifications

Qi Feng is skilled in molecular biology, pharmacological research, and immunological techniques. His expertise spans both in vitro and in vivo models, and he has a strong foundation in scientific collaboration, data analysis, and academic publishing. His interdisciplinary training and international research experience make him a valuable contributor to the global scientific community.

Research Focus

Qi Feng’s research centers on the pathophysiology and treatment of diabetic nephropathy, with broader interests in renal pharmacology, immunology, ferroptosis, and metabolic disorders. His interdisciplinary approach integrates chemical biology, bioengineering, and translational medicine to uncover new therapeutic targets and strategies for kidney-related diseases.

Conclusion

Dr. Qi Feng stands out as a remarkably suitable candidate for the Best Researcher Award. His research excellence, forward-thinking contributions, and dedication to advancing internal medicine and nephrology position him at the forefront of medical science. Awarding Dr. Feng would not only recognize his achievements but also inspire continued innovation in tackling kidney-related diseases.

Publications

Title: Lactate and Lactylation in AKI‐to‐CKD: Epigenetic Regulation and Therapeutic Opportunities
Authors: Yi Hou, Dongwei Liu, Zuishuang Guo, Cien Wei, Fengyu Cao, Yue Xu, Qi Feng, Fengxun Liu
Year: 2025
Journal: Cell Proliferation
Title: Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways
Authors: Qi Feng, Xiaoyue Yu, Junwei Xie, Fengxun Liu, Xiaonan Zhang, Shiyang Li, Yixue Wang, Shaokang Pan, Dongwei Liu, Zhangsuo Liu
Year: 2025
Journal: Phytomedicine
Title: RNA 5-Methylcytosine Modification: Regulatory Molecules, Biological Functions, and Human Diseases
Authors: Yanfang Lu, Liu Yang, Qi Feng, Yong Liu, Xiaohui Sun, Dongwei Liu, Long Qiao, Zhangsuo Liu, Chengqi Yi
Year: 2024
Journal: Genomics, Proteomics & Bioinformatics
Title: Mitochondria-associated endoplasmic reticulum membrane (MAM): a dark horse for diabetic cardiomyopathy treatment
Authors: Yong Liu, Jin-Ling Huo, Kaidi Ren, Shaokang Pan, Hengdao Liu, Yifeng Zheng, Jingfang Chen, Yingjin Qiao, Yang Yang, Qi Feng
Year: 2024
Journal: Cell Death Discovery
Title: Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities
Authors: Jia Li, Jiayu Duan, Chaoyang Hua, Shaokang Pan, Guangpu Li, Qi Feng, Dongwei Liu, Zhangsuo Liu
Year: 2024
Journal: Burns & Trauma

Qi Feng | Internal Medicine | Best Researcher Award